HUM News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

HU

Mkt Cap

$45.46B

Volume

433.12K

Next Earnings

November 4th

Chart Financials Earnings News About Dividends Insider Filings

Can Centene Sustain Its Turnaround Amid Membership Pressure?Centene Corporation reported Q2 2026 adjusted EPS of $2.51, marking a significant recovery from a loss a year prior, driven by improved medical cost trends and better execution. The company expects Medicaid membership to decline 8%-9% in 2026, but profitability improvements in Marketplace and Medicare segments, combined with higher Medicaid rates and cost initiatives, support continued recovery. CNC reaffirmed its 2026 adjusted EPS guidance above $4.80.Zacks Investment Research · Sep 17, 2026

Global Value-Based Healthcare Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsightThe value-based healthcare market is experiencing robust growth, projected to reach USD 62 billion by 2034 from USD 16.5 billion in 2025, with a CAGR of ~16%. The shift from fee-for-service to outcome-based payment models is driven by rising healthcare costs, chronic disease burden, and government reimbursement reforms. North America dominates with 72% market share, while Asia-Pacific is expected to record the fastest growth. Key players include Optum, Humana, Evolent Health, Agilon Health, and Privia Health.GlobeNewswire Inc. · Sep 16, 2026

Is Invesco S&P 500 Pure Value ETF (RPV) a Strong ETF Right Now?The Invesco S&P 500 Pure Value ETF (RPV) is a smart beta ETF with $1.75 billion in assets that tracks the S&P 500 Pure Value Index. It has delivered 19.31% year-to-date returns and 26.47% over the past year with a 0.35% expense ratio. The fund holds 125 stocks with heavy exposure to Financials (20.4%), Healthcare, and Consumer Staples sectors. While RPV offers reasonable value-focused exposure, cheaper alternatives like Vanguard's VTV (0.03% expense ratio) and Schwab's SCHD (0.06% expense ratio) may be more cost-effective for investors.Zacks Investment Research · Sep 16, 2026

BTSG's Specialty Pharmacy Sales Up 30%: Will the Growth Continue?BrightSpring Health Services (BTSG) reported strong Q2 2026 results with Specialty and Infusion revenue growing 30% and scripts rising 31%, driven by branded limited distribution drugs (LDDs) and expansion into rare and orphan therapies. The company added two new LDDs, bringing its portfolio to 155 programs with 12 launched in 2026. Pharmacy Solutions adjusted EBITDA increased 44% to $180 million. Peers Cigna and Humana also showed strength in specialty pharmacy segments, though with different growth drivers.Zacks Investment Research · Sep 10, 2026

Should Invesco S&P 500 Pure Value ETF (RPV) Be on Your Investing Radar?The Invesco S&P 500 Pure Value ETF (RPV) offers broad exposure to large-cap value stocks with a 0.35% expense ratio and $1.76 billion in assets. The ETF has returned 20.17% year-to-date and 28.46% over the past year, with a medium risk profile (beta of 0.82). It carries a Zacks ETF Rank of 3 (Hold), with alternatives like Vanguard Morningstar Value ETF (VTV) and Schwab U.S. Dividend Equity ETF (SCHD) offering lower expense ratios.Zacks Investment Research · Sep 7, 2026

UnitedHealth Stock Rises 39% in 6 Months: Should Investors Still Buy?UnitedHealth (UNH) has surged 38.8% over six months as medical-cost pressures ease and confidence improves. The company's medical care ratio fell to 85.3%, medical costs declined 2%, and 2026 EPS estimates rose 21.2% to $19.82. Despite the rally, UNH trades below its five-year median valuation and analyst price targets, suggesting further upside potential. The stock carries a Zacks Rank #2 (Buy) rating.Zacks Investment Research · Sep 4, 2026

3 Stocks Doing the Heavy Lifting in Healthcare’s ReboundThe healthcare sector is rebounding after a lackluster start to 2026, driven by rotation from tech and stabilizing costs. Three stocks are leading the rally: Eli Lilly (up 11% in a month) on strong GLP-1 drug sales and new oral pill approval; Humana (up 18% in a month) as medical utilization moderates and margins widen; and DexCom (up 15% in a month) expanding into non-insulin Type 2 diabetes markets with landmark trial data.Investing.com · Jun 18, 2026

CVS Health Stock Is Soaring. Could the Rally Just Be Getting Started?CVS Health stock has surged 24% over the past month following strong Q1 earnings that beat analyst expectations, with revenue up 6.2% to $100.4B and EPS up 62% to $2.30. The company raised full-year guidance and is benefiting from improved margins in its Aetna insurance segment and growth from Rite Aid store acquisitions. However, the company carries significant debt of $86.4B in long-term obligations, though it is gradually reducing overall leverage.The Motley Fool · May 20, 2026

Humana, Inc. Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Social Security Numbers, Medical Claims, and Patient Account DataHumana Inc. experienced a data breach in August 2025 caused by a vendor's Oracle software vulnerability, exposing sensitive personal information including Social Security numbers, medical claims, and patient account data. Edelson Lechtzin LLP has launched a class action investigation to pursue legal remedies on behalf of affected individuals. Humana has reported no current evidence of identity theft or misuse from the incident.GlobeNewswire Inc. · Apr 20, 2026

CVS Health Just Got a $13 Billion Reprieve. Here's Why the Stock Could Keep Climbing.CVS Health received positive news when Medicare finalized a 2.5% payment increase to providers, significantly better than the initially proposed 0.09% increase. This $13 billion boost to insurers like CVS's Aetna unit improves profitability outlook. Trading at 11x forward earnings compared to peers at 15-20x, CVS appears undervalued with potential to reach $90-$100 per share, supported by 3.4% dividend yield and expected earnings growth.The Motley Fool · Apr 13, 2026

HU

HUMHumana Inc.

HUM

Pay with—

Available Balance0.00

Your PositionYou don't own any HUM yet.

Related Tickers

Earnings

Dividends

Ex Oct 30

Amount$0.89

PaysNov 27

Last · Jun 26Quarterly

Amount$0.89

Yield0.95%

Annual$3.54